Elon Musk’s Neuralink has unveiled a dramatic milestone: its brain chip can move robotic limbs using only the wearer’s thoughts. In a video released on X, Rocky Stoutenburgh, paralyzed since 2006, raises a robotic arm to his face and kisses it, a scene the company says demonstrates how the device can extend digital control to physical devices such as assistive arms. Neuralink notes the implant is still in clinical trials, focusing on initial safety and basic functionality as it tests how well the system interprets brain activity and translates signals into device commands.
As of September, Neuralink had implanted its device in 12 people since January 2024. The first participant was paralyzed after a spinal cord injury, and others have had spinal cord injuries or amyotrophic lateral sclerosis (ALS). Musk said more than 10,000 people have signed up for Neuralink’s patient registry, hoping to participate in trials for the device. Neuralink is one of several groups researching brain-computer interfaces (BCIs), with studies exploring their use for cerebral palsy, dementia, stroke, and other conditions.
Beyond the hype, experts emphasize that safety, consent, and data privacy must guide any rollout. The current demonstrations show that a brain signal can control a robotic limb, but questions remain about long-term safety, device longevity, and how widely such technology can be offered. The technology rests on a brain-computer interface (BCI) that interprets neural activity and converts it into commands for external tools. While Neuralink’s focus is mobility and autonomy for paralysis, researchers caution that this is early-stage research with substantial regulatory and ethical considerations ahead.
BCIs work by recording neural signals and translating them into actionable commands for devices. Neuralink’s updates describe extending control from computers and phones to physical devices like robotic arms, marking a shift from assistive tech to more tangible mobility. The trials involve participants with spinal cord injuries and ALS, with ongoing monitoring of safety, biocompatibility, and functional gains. As other studies indicate potential benefits for diverse conditions, the broader landscape emphasizes rigorous evaluation before broader access.
